Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

528.04 +30.03 (+6.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,879,133
Open 503.76
Bid (Size) 524.75 (40)
Ask (Size) 527.00 (40)
Prev. Close 498.01
Today's Range 501.53 - 529.14
52wk Range 362.50 - 529.14
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value. 
Via The Motley Fool
News headline image
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire

Performance

YTD
+16.8%
+16.8%
1 Month
+24.2%
+24.2%
3 Month
+20.4%
+20.4%
6 Month
+16.8%
+16.8%
1 Year
+15.5%
+15.5%

More News

Read More
News headline image
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗
Via Chartmill
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals ↗
Via Chartmill
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
Via StockStory
Topics Artificial Intelligence
News headline image
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
Via MarketBeat
Topics ETFs
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
3 of Wall Street’s Favorite Stocks to Consider Right Now
Via StockStory
News headline image
2 Reasons to Like VRTX (and 1 Not So Much)
Via StockStory
News headline image
If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
Via The Motley Fool
News headline image
3 Market-Beating Stocks Worth Investigating
Via StockStory
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
Via The Motley Fool
Topics ETFs
News headline image
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
Via The Motley Fool
News headline image
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Best Stocks to Invest $500 in Right Now ↗
Via The Motley Fool
News headline image
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges
Via StockStory

Frequently Asked Questions

Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 528.04
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 07/02/26 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 136.99B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 137B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.